Corcept Therapeutics Incorporated (NASDAQ: CORT) reported that patients with amyotrophic lateral sclerosis who received its experimental drug dazucorilant showed an ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE